Clinical Observation on Shugan Xiaoluo Pills in the Treatment of Granulomatous Lobular Mastitis in the Mass Stage of Liver Stagnation And Phlegm Coagulation Type
Objective:To study and analyze the clinical effect of Shugan Xiaolou Pill in treating granulomatous mastitis(GLM)with liver depression and phlegm coagulation syndrome in the mass stage.Methods:From December 2021 to De-cember 2022,60 patients with liver depression and phlegm coagulation syndrome in GLM mass stage were selected and randomly divided into control group and observation group with 30 cases in each group.Both groups were given routine treatment,the control group was given methylprednisolone,and the observation group was given Shugan Xiaoyu Pill.After 12 weeks of treatment,the clinical efficacy、clinical syndrome score、pain degree、mass size and adverse reactions of the two groups were compared.Results:After treatment,the clinical syndrome score of the two groups was significantly lower than that before treatment,and the clinical syndrome score of the observation group was lower than that of the control group,P<0.05;The VAS scores of the two groups were significantly lower than before treatment,P<0.05,but after treatment,the VAS scores of the two groups were compared,P>0.05;The diameter of the body surface mass in both groups was smaller than that before treatment,and the diameter of the mass in the observation group was more significant than that in the control group,P<0.05.After 12 weeks of treatment,the total effective rate of the observationgroup was higher than that of the control group,P<0.05.The adverse reactions of the two groups were compared,P>0.05.Conclusion:Shugan Xiaoluo Pill is effective in treating GLM patients with stagnation of liver-qi and phlegm-coagulation,which can improve the clinical symptoms,reduce the mass and relieve the pain without increasing adverse reactions.
Granulomatous mastitisMass stageSyndrome of liver depression and phlegm coagulationShugan Xiaoyu Pill
国家科技期刊平台
NSTL
万方数据
